# Generate Biomedicines, Inc. Common Stock (GENB)

> Generate Biomedicines, Inc. Common Stock (GENB) trades at $10.52 (+6.91%) as of 6:55:29 AM EST on Nov 19, 2026, -19.53% over the past month. Market cap is $1.34B, with 8.9 days to cover in short interest.

Canonical: https://massive.com/quote/genb
Data as of: 2026-11-19T11:55:29.580Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$10.52** +0.68 (+6.91%)
As of 6:55:29 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Generate Biomedicines, Inc. Common Stock (GENB) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +5.49% |
| 1W | -23.05% |
| 1M | -19.53% |
| YTD | -17.94% |
| 1Y | -17.94% |
| 52-wk range | $9.68 – $22.67 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for GENB: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $9.68 – $10.54 |
| Open | $9.88 |
| Prev close | $9.84 |
| Volume | 1.05M |
| Market cap | $1.34B |
| Shares out | 129.1M |

## Valuation and profitability ratios

Valuation and profitability ratios for Generate Biomedicines, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 75.46 |
| P/B | 3.52 |
| P/FCF | — |
| ROE | -58.8% |
| ROA | -43.4% |
| Debt/Equity | 0.05 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Generate Biomedicines, Inc. Common Stock (GENB) insider trading](https://massive.com/quote/genb/insider-trading.md): open-market Form 4 buys and sells by Generate Biomedicines, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Generate Biomedicines, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2026.”
- Aug 26, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Draft copies of three posters submitted by Generate Biomedicines, Inc. include results of ongoing clinical trials sponsored by the Company, entitled: 'GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients'; 'SOLAIRIA-1 & SOLAIRIA-2: Two Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895, a long-acting anti-TSLP antibody, in severe uncontrolled asthma'; and 'GB-0895, a High-Affinity Anti-TSLP Antibody, Demonstrates Potent and Sustained Pharmacological Activity in Adults with COPD.'”
- Mar 2, 2026 · Charter amendment
  “The Company filed its amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on March 2, 2026... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.”

## GENB short interest

How heavily GENB is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.9 |
| Short interest | 9.08M |
| Avg volume | 1.02M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## GENB news

The latest news and headlines about Generate Biomedicines, Inc. Common Stock (GENB).

- [2027 Could Finally Be the Year Cancer Is on the Ropes!](https://www.globenewswire.com/news-release/2026/10/30/3391989/0/en/2027-could-finally-be-the-year-cancer-is-on-the-ropes.html) · GlobeNewswire Inc. · Oct 29, 2026 · positive sentiment
- [Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition](https://www.globenewswire.com/news-release/2026/10/16/3382652/0/en/pharmaceutical-market-research-global-industry-to-reach-usd-3-22-trillion-by-2035-as-biologics-ai-driven-drug-discovery-and-manufacturing-investments-reshape-competition.html) · GlobeNewswire Inc. · Oct 16, 2026 · positive sentiment
- [Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday](https://www.fool.com/investing/2026/07/07/cathie-wood-goes-bargain-hunting-3-stocks-she-just/?source=iedfolrf0000001) · The Motley Fool · Jul 7, 2026 · positive sentiment
- [Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market](https://www.fool.com/investing/2026/06/27/nvidia-owns-under-radar-stock-trillion-market-genb/?source=iedfolrf0000001) · The Motley Fool · Jun 27, 2026 · positive sentiment
- [A Deep Dive Into Nvidia’s Latest Portfolio Moves](https://www.investing.com/analysis/a-deep-dive-into-nvidias-latest-portfolio-moves-200680639) · Investing.com · May 20, 2026 · positive sentiment

## About Generate Biomedicines, Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| IPO | $16.00 on Feb 27, 2026 |

[Generate Biomedicines IPO page](https://massive.com/quote/genb/ipo.md)

[Company website](https://www.generatebiomedicines.com)

## FAQ

### What is the Generate Biomedicines, Inc. Common Stock (GENB) stock price today?

Generate Biomedicines, Inc. Common Stock (GENB) is trading at $10.52 (+6.91% on the day) as of 6:55:29 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Generate Biomedicines, Inc. Common Stock?

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug…

### What is the short interest in GENB?

As of Oct 30, 2026, GENB has 9.08M shares short and 8.9 days to cover.

### What exchange is GENB listed on?

Generate Biomedicines, Inc. Common Stock (GENB) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time GENB quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=GENB`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Generate Biomedicines, Inc. Common Stock (GENB) insider trading](https://massive.com/quote/genb/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
